Patents Examined by Misook Yu
  • Engineered anti-TSLP antibody
    Patent number: 8232372
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: July 31, 2012
    Assignee: Schering Corp.
    Inventors: Leonard G. Presta, Rene de Waal Malefyt
  • Humanized Fc?RIIB-specific antibodies and methods of use thereof
    Patent number: 8216579
    Abstract: The present invention relates to humanized Fc?RIIB antibodies, fragments, and variants thereof that bind human Fc?RIIB with a greater affinity than said antibody binds Fc?RIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express Fc?RIIB.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: July 10, 2012
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Methods and kits for detection of cancer metastasis
    Patent number: 8211659
    Abstract: The invention provides a method of detecting metastasis of cancers in the body fluids from a mammal, the method comprising the steps of: (a) providing the body fluids from the mammal; and (b) the measurement of the CAS protein level or CAS polypeptide level in the body fluids to screen or diagnose the metastatic cancers. Also provided is a kit for the method of the invention.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: July 3, 2012
    Assignees: Tungs' Taichung Metroharbor Hospital
    Inventors: Ming-Chung Jiang, Chin-Shaw Stella Tsai, Min-Che Tung, Jai-Nien Tung
  • Method for enhancing or inhibiting insulin-like growth factor-I
    Patent number: 8206706
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: June 26, 2012
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses
    Patent number: 8207309
    Abstract: Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: June 26, 2012
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Beka Solomon, Sara Orgad, Itai Benhar, Ronit Rosenfeld
  • Anti-CD151 antibodies and their use in the treatment of cancer
    Patent number: 8198413
    Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: June 12, 2012
    Assignee: Pierre Fabre Medicament
    Inventor: Jean-François Haeuw
  • Antibodies to NTB-A
    Patent number: 8193320
    Abstract: Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: June 5, 2012
    Assignee: ARCA Biopharma, Inc.
    Inventors: Arie Abo, Wouter Korver
  • Methods and compositions for tumor vaccination and therapy
    Patent number: 8193313
    Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: June 5, 2012
    Assignee: The Rockefeller University
    Inventor: Robert B. Darnell
  • Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
    Patent number: 8187595
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: May 29, 2012
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
    Patent number: 8188228
    Abstract: A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: May 29, 2012
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Pia M. Challita-Eid, Mary Faris, Rene S. Hubert, Wangmao Ge, Aya Jakobovits
  • Multivalent carriers of bi-specific antibodies
    Patent number: 8188239
    Abstract: Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: May 29, 2012
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, William J. McBride, Zhengxing Qu
  • Antibodies that bind to EphA2 and methods of use thereof
    Patent number: 8183357
    Abstract: Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: May 22, 2012
    Assignee: MacroGenics, Inc.
    Inventors: Jennie P. Mather, Penelope E. Roberts
  • Agent for inducing apoptosis comprising MSX1 or a gene encoding the same as an active ingredient
    Patent number: 8183218
    Abstract: The present invention relates to a novel use of Msx1 protein or a nucleotide encoding the same for inducing apoptosis. The Msx1 of the present invention induces apoptosis through direct interaction with p53 via a homeodomain and such interaction leads to increased stability, and/or nuclear localization of p53 in cells. The Msx1 or homeodomain thereof can be effectively used for the treatment of tumors, in which wild-type p53 protein has lost its function by some mechanism that inactivates p53 proteins.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: May 22, 2012
    Assignee: Sungkyunkwan University Foundation for Corporate Collaboration
    Inventors: Je-Ho Lee, Kyoungsook Park
  • Compositions and methods of use for MGD-CSF in disease treatment
    Patent number: 8178109
    Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: May 15, 2012
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
  • Molecules of the card-related protein family and uses thereof
    Patent number: 8178661
    Abstract: Novel CARD-9, CARD-10, or CARD-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-9, CARD-10, or CARD-11 proteins, the invention further provides CARD-9, CARD-10, or CARD-11, fusion proteins, antigenic peptides and anti-CARD-9, CARD-10, or CARD-11 antibodies. The invention also provides CARD-9, CARD-10, or CARD-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-9, CARD-10, or CARD-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: May 15, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: John Bertin
  • PCan065 antibody compositions and methods of use
    Patent number: 8173434
    Abstract: The invention provides isolated anti-PCan065 antibodies that bind to PCan065. The invention also encompasses compositions comprising an anti-PCan065 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-PCan065 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-PCan065 antibodies. The invention encompasses a method of producing the anti-PCan065 antibodies. Other aspects of the invention are a method of killing an PCan065-expressing cancer cell, comprising contacting the cancer cell with an anti-PCan065 antibody and a method of alleviating or treating an PCan065-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-PCan065 antibody to the mammal.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: May 8, 2012
    Assignee: Diadexus, Inc.
    Inventors: Rong A. Fan, Kirstin L. Krall
  • Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer
    Patent number: 8173381
    Abstract: A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: May 8, 2012
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Mary Faris, Rene S. Hubert, Daniel Afar, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
  • Monoclonal antibodies against claudin-18 for treatment of cancer
    Patent number: 8168427
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Grant
    Filed: November 24, 2006
    Date of Patent: May 1, 2012
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Dirk Usener, Stefan Fritz, Cristoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schroder, Philippe Thiel
  • Gene encoding labyrinthin, a marker for cancer
    Patent number: 8163883
    Abstract: A cDNA molecule that encodes a protein designated Labyrinthin (Lab) isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: April 24, 2012
    Assignee: Mission Therapeutics, Inc.
    Inventor: James Radosevich
  • Method of detecting cancer and evaluating cancer prognosis
    Patent number: 8158373
    Abstract: A method of detecting cancer in a subject is provided. One step of the method includes obtaining a bodily sample from the subject. Next, the level of pro-prion protein (pro-PrP) in the bodily sample is detected. The level of pro-PrP in the bodily sample is then compared to a control level. An increased level of pro-PrP in the bodily sample as compared to the control level indicates that the subject has cancer or an elevated risk of having cancer.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: April 17, 2012
    Assignee: Case Western Reserve University
    Inventors: Man-Sun Sy, Wei Xin